Amylyx Resets As A Clinical-Stage Company, Withdrawing Relyvrio

Workforce Will Be Cut By 70%

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The ALS treatment Relyvrio was removed from the market as expected following a Phase III trial failure.

empty cabinet
Relyvrio was withdrawn from the market • Source: Shutterstock

With the removal of Relyvrio (sodium phenylbutyrate/taurursodiol) from the market, Amylyx Pharmaceuticals, Inc. will lose its sole commercial revenue stream and return its focus to pipeline development. The company announced on 4 April that it will withdraw Relyvrio from the US and Canada, where it is sold as Albrioza, immediately due to lack of efficacy for amyotrophic lateral sclerosis (ALS).

Key Takeaways

  • The withdrawal of Relyvrio from the market for ALS was expected but is a disappointment for the company, investors and patients.

The update was expected after the Cambridge, MA-based company announced in March that the confirmatory Phase III PHOENIX trial testing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 
• By Andrew McConaghie

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains